Brief: Anixa Biosciences Announces Maximum Tolerated Dose Reached In Trial Of Preventative Breast Cancer Vaccine
08/12/2022 15:49
Dec 8 (Reuters) - Anixa Biosciences Inc ANIX.O :
* ANIXA BIOSCIENCES ANNOUNCES MAXIMUM TOLERATED DOSE REACHED
IN
TRIAL OF PREVENTATIVE BREAST CANCER VACCINE
* ANIXA BIOSCIENCES INC - MAXIMUM TOLERATED DOSE (MTD) HAS
BEEN
REACHED IN PHASE 1A TRIAL OF ITS PREVENTATIVE BREAST CANCER
VACCINE
* ANIXA BIOSCIENCES INC - LOOK FORWARD TO PRESENTING
COMPLETE
IMMUNOLOGICAL DATA FROM TRIAL AT A SCIENTIFIC CONFERENCE OR
SIMILAR SETTING IN Q2 OF 2023
Source text for Eikon: ID:nPnl0qBla
Further company coverage: ANIX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine